Overview

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Epoetin Alfa